Pharmaceutical Business Review
Return to: PBR Home | Companies

ImmunoGen Inc

ImmunoGen Inc
830 Winter Street
United States of America
Phone: 1 781 8950600
Fax: 17-81-8950611

No. employees: 308
Turnover: 60.00 (US$m)
Financial year end: December

Company Overview

Top Competitors

Key Employees

Stephen C. McCluski

Chairman, Executive Board

Daniel M. Junius

Director, Executive Board

Mark J. Enyedy

President, Chief Executive Officer, Director, Executive Board

Dean Mitchell

Director, Non Executive Board

Richard Wallace

Director, Non Executive Board

Howard Pien

Director, Non Executive Board

Joseph J. Villafranca, Ph.D.

Director, Non Executive Board

Nicole Onetto, M.D.

Director, Non Executive Board

Mark Goldberg, M.D.

Director, Non Executive Board

Kristine Peterson

Director, Non Executive Board

Thomas Ryll, Ph.D.

Vice President - Product Strategy and Program Management, Senior Management

Anna Berkenblit, M.D.

Vice President, Chief Medical Officer, Senior Management

Peter Williams

Vice President - Business Development, Senior Management

Theresa Wingrove, Ph.D.

Vice President - Regulatory Affairs, Senior Management

David Johnston

Chief Financial Officer, Executive Vice President, Senior Management

Craig Barrows

Vice President, Secretary, General Counsel, Senior Management

Richard J. Gregory, Ph.D.

Executive Vice President - Research, Chief Scientific Officer, Senior Management


830 Winter Street,
United States of America
Phone: 1 781 8950600
Fax: 1 781 8950611

ImmunoGen Europe Ltd

3rd Floor,
24 Chiswell Street,
United Kingdom

ImmunoGen Securities Corp

Suite 830,
Winter Street,
Waltham ,
United States of America



  • Product Pipeline:
  • Wholly Owned
  • Mirvetuximab soravtansine (IMGN853)
  • Coltuximab Ravtansine
  • IMGN529
  • IMGN779
  • IMGN632
  • Partner
  • Kadcyla
  • Anetumab ravtansine (BAY 94-9343)
  • Indatuximab ravtansine (BT-062)
  • Isatuximab (SAR650984)
  • SAR428926
  • SAR566658
  • LY3076226
  • PCA062